041830.Kq
The company operates in the Advanced Medical Equipment & Technology industry, specializing in the design, development, and sale of medical devices and equipment, primarily generating revenue through product sales and related services.
Business. The company operates in the Advanced Medical Equipment & Technology industry, specializing in the design, development, and sale of medical devices and equipment, primarily generating revenue through product sales and related services.
Analyst recommendations
2 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the Advanced Medical Equipment & Technology industry, specializing in the design, development, and sale of medical devices and equipment, primarily generating revenue through product sales and related services.
The company maintains a strong liquidity position, with a current ratio of 6.48 and cash and equivalents amounting to 52,371,957,700 KRW, indicating a robust ability to meet short-term obligations. The debt-to-equity ratio is low at 0.03, suggesting minimal reliance on debt financing and a conservative capital structure. The company's price-to-book ratio of 1.93 and price-to-tangible-book ratio of 1.93 reflect a moderate premium over its book value, consistent with its industry positioning.
Profitability metrics show the company is performing well relative to industry standards. The return on equity (ROE) of 9.64% and return on assets (ROA) of 8.48% indicate efficient use of equity and assets to generate profits. The operating margin, derived from operating income of 36,752,659,430 KRW on revenue of 233,948,308,380 KRW, is strong, suggesting effective cost management and pricing power.
The company's revenue is primarily concentrated in its core medical equipment and technology segment, with no disclosed geographic diversification in the provided data. This concentration may expose the company to regional market risks, although the absence of specific geographic breakdowns limits a more detailed assessment.
The company's growth trajectory appears stable, with a strong operating cash flow of 35,777,960,280 KRW and free cash flow of 25,968,595,200 KRW. Analysts have assigned a mean price target of 44,000 KRW, slightly below the current market price of 46,000 KRW, indicating a generally positive but cautious outlook.
Risk factors are minimal, with low liquidity and dilution risks identified. The company has no immediate filing-based liquidity or dilution flags, and the low dilution potential is supported by the absence of recent equity issuances or ATM/shelf disclosures. The conservative capital structure and strong cash reserves further mitigate financial risk.
Recent events, as reflected in the latest financial data, show consistent performance with no significant deviations in revenue or profitability. The company's capital expenditure of -7,421,844,390 KRW indicates a focus on maintaining rather than expanding its asset base, which aligns with its current financial strategy.
- The company has a strong liquidity position with a current ratio of 6.48 and significant cash reserves.
- Profitability metrics, including ROE of 9.64% and ROA of 8.48%, indicate efficient use of capital and assets.
- The company's capital structure is conservative, with a low debt-to-equity ratio of 0.03.
- Analysts have a cautiously positive outlook, with a mean price target of 44,000 KRW.
- The company's revenue is concentrated in its core medical equipment and technology segment, with no disclosed geographic diversification.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 2 905,50 |
| Revenue | —no estimate | —no estimate | 270,2B KRW |
| Operating income | —no estimate | —no estimate | 45,7B KRW |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Ev To Operating Cash Flowenterprise_value / operating_cash_flow
- Return On Equitynet_income / total_equity
- Price To Earningsmarket_price / (net_income / shares_outstanding_diluted)
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- 041830.KQ Market data — financials · 2026-05-26
- InBody Co Ltd Market data — analyst estimates · 2026-05-26